NASDAQ:REPH Recro Pharma (REPH) Stock Price, News & Analysis → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Free REPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.47▼$2.1152-Week Range N/AVolume141,800 shsAverage Volume126,298 shsMarket Capitalization$117.93 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Recro Pharma alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Recro Pharma Stock (NASDAQ:REPH)Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. REPH Stock News HeadlinesJanuary 30, 2024 | wsj.comFuji Pharma Co. Ltd.November 7, 2023 | markets.businessinsider.comHere's what Wall Street expects from Recro Pharma's earnings reportApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) August 16, 2023 | theguardian.comUS supreme court halts Purdue Pharma deal that shields Sacklers from lawsuitsAugust 9, 2023 | markets.businessinsider.comWhat Wall Street expects from Recro Pharma's earningsAugust 3, 2023 | investing.comMankind Pharma Ltd (MNKI)June 30, 2023 | bizjournals.comBaudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumpsJune 24, 2022 | benzinga.comPomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTLApril 25, 2024 | Stansberry Research (Ad)See this before next week's Fed meetingSee this before next week's Fed Meeting Doc Eifrig just released a new video detailing "the perilous moment Americans are in right now." Angry voters, mounting government debt, and blood in the streets… But he's got a way out – a unique way to come out on top no matter who wins this presidential election. (Last time we shared this, it led to a 995% gain.) April 20, 2022 | reuters.comSocietal CDMO IncMarch 22, 2022 | finanznachrichten.deRecro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and TransformationMarch 22, 2022 | finance.yahoo.comIs Recro Pharma (REPH) a Worthy Investment?March 1, 2022 | benzinga.comRecap: Recro Pharma Q4 EarningsFebruary 23, 2022 | finance.yahoo.comRecro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego FacilityFebruary 22, 2022 | finance.yahoo.comRecro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022January 26, 2022 | finance.yahoo.comRecro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer PreventionJanuary 3, 2022 | finance.yahoo.comRecro to Present at H.C. Wainwright BioConnect 2022 ConferenceDecember 8, 2021 | finance.yahoo.comDo Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?November 2, 2021 | finance.yahoo.comRecro to Report Financial Results for Third Quarter 2021 on November 9, 2021October 27, 2021 | finance.yahoo.comRecro Enters Into Master Commercial Supply and Services Agreement With OtsukaSeptember 21, 2021 | marketwatch.comRecro Pharma Signs Renewable Energy Agreement with Georgia PowerSeptember 21, 2021 | finance.yahoo.comRecro Signs Renewable Energy Agreement With Georgia PowerSeptember 16, 2021 | finance.yahoo.comRecro Pharma (REPH) Moves to Buy: Rationale Behind the UpgradeAugust 16, 2021 | bizjournals.comRecro Pharma goes bicoastal with 'transformative' acquisition of San Diego firm for $50MAugust 13, 2021 | marketwatch.comRecro Pharma Buys San Diego-Based Irisys for $50 Million >REPHAugust 13, 2021 | finance.yahoo.comRecro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMOAugust 10, 2021 | finance.yahoo.comRecro Announces Entry Into Letter of Intent for Acquisition of a Full Service CDMOSee More Headlines Receive REPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recro Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/01/2022Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:REPH CUSIPN/A CIK1588972 Webwww.recropharma.com Phone(770) 534-8239Fax484-395-2471Employees185Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-11,370,000.00 Net Margins-15.15% Pretax Margin-15.09% Return on Equity-56.66% Return on Assets-11.14% Debt Debt-to-Equity Ratio2.27 Current Ratio3.24 Quick Ratio2.74 Sales & Book Value Annual Sales$75.36 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / BookN/AMiscellaneous Outstanding Shares56,424,000Free Float48,412,000Market Cap$117.93 million OptionableOptionable Beta1.08 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesJ. David EnloePresident, Chief Executive Officer & DirectorRyan D. LakeChief Financial Officer & TreasurerRichard SidwellChief Scientific Officer & Senior Vice PresidentStephen DressDirector-Information TechnologyDavid SmithwickVice President-Technical OperationsKey CompetitorsRelmada TherapeuticsNASDAQ:RLMDGlycoMimeticsNASDAQ:GLYCInterCureNASDAQ:INCRPDS BiotechnologyNASDAQ:PDSBCoya TherapeuticsNASDAQ:COYAView All Competitors REPH Stock Analysis - Frequently Asked Questions How were Recro Pharma's earnings last quarter? Recro Pharma, Inc. (NASDAQ:REPH) posted its earnings results on Tuesday, March, 1st. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.07) by $0.03. Recro Pharma had a negative net margin of 15.15% and a negative trailing twelve-month return on equity of 56.66%. During the same quarter last year, the firm posted ($0.48) EPS. What other stocks do shareholders of Recro Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Recro Pharma investors own include TherapeuticsMD (TXMD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Flexion Therapeutics (FLXN), Nabriva Therapeutics (NBRV), SCYNEXIS (SCYX), Verastem (VSTM), Corbus Pharmaceuticals (CRBP) and Ocular Therapeutix (OCUL). This page (NASDAQ:REPH) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recro Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
